🐕 MELOXICAM 5 mg🐈 for injection
🚑 It has anti-inflammatory, analgesic and antipyretic effects.
Treats dogs and cats in diseases of the musculoskeletal system (fractures, post-traumatic arthropathies, sprains of ligaments and tendons, degenerative joint disease, chronic degenerative joint diseases, etc.), as well as to reduce pain in the postoperative period.
DOSAGE:
🔹 Dogs: single subcutaneous or intravenous injection at a dose of 0.2 mg of meloxicam per 1 kg of animal body weight, which corresponds to 0.04 ml of the drug per 1 kg of body weight.

If necessary, the injection is repeated after 24 hours.
🔹 Cats: single subcutaneous injection at a dose of 0.2 mg meloxicam per 1 kg of animal body weight, which corresponds to 0.04 ml of the drug per 1 kg of body weight.
If necessary, the injection is repeated after 24 hours.
To facilitate the use and dosing of the drug in small animals, it is recommended to dilute it with a sterile solvent (water for injection) in a ratio of 1:10.
When using the drug in animals, swelling may occur at the injection site, which gradually disappears.

Contraindication:
Hypersensitivity to the components of the drug or to drugs with a similar effect, e.g. other NSAIDs, including acetylsalicylic acid.

⚠ Do not use the drug in animals with ulcers and bleeding symptoms in the gastrointestinal tract, cardiovascular disorders, liver and kidney disorders.

⚠ Do not use in pregnant or lactating animals.
⚠ Do not use concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs, and anticoagulants.

Composition of the drug:
1 ml of the drug contains the active substance:
meloxicam - 5 mg.

Excipients: meglumine, glycine, trilon B, PEG-400, ethyl alcohol, water for injection.

Pharmacological properties:
ATCvet classification code: QM01A - anti-inflammatory and antirheumatic veterinary drugs, non-steroidal.

Meloxicam belongs to non-steroidal anti-inflammatory drugs (NSAIDs) from the oxicam group, it is a selective COX-2 inhibitor. It has anti-inflammatory, analgesic and antipyretic effects. The mechanism of action of meloxicam is associated with a decrease in prostaglandin biosynthesis due to inhibition of the enzymatic activity of COX-2, which is involved in the synthesis of prostaglandins in the inflammatory focus, has a minor effect on COX-1, which reduces the risk of adverse events.

The relative bioavailability of meloxicam is almost 100%. After intramuscular injection of the drug at a dose of 5 mg meloxicam per 1 kg of body weight, its maximum concentration (Cmax) in blood plasma is 1.62 μg/ml and is achieved in about 60 minutes.

Meloxicam binds well to plasma proteins, especially albumin (99%). It penetrates the synovial fluid, the concentration in the synovial fluid is about 50% of the concentration in plasma. The volume of distribution (Vd) is small, on average 11 l.
Meloxicam is almost completely metabolized in the liver with the formation of 4 inactive derivatives. The major metabolite, 5'-carboxymeloxicam (60% of the administered dose), is formed by oxidation of the intermediate metabolite, 5'-hydroxymethylmeloxicam, which is also excreted, but to a lesser extent (9% of the dose).

It is excreted in bile and urine, mainly in the form of metabolites. In unchanged form, less than 5% of the daily dose is excreted in bile, in urine - in trace amounts. The mean half-life (T½) is 20 hours. The mean plasma clearance is 8 ml/min. Meloxicam shows linear pharmacokinetics at doses of 7.5-15 mg after intramuscular injection. Moderate hepatic or renal failure does not significantly affect the pharmacokinetics of meloxicam.

Storage:
A dry, dark place inaccessible to children at a temperature of 10 °C to 25 °C.
After first taking the medicine from the bottle - 28 days.

The shelf life is 3 years from the date of production.